Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy

 
• By Sten Stovall
HIV
Biktarvy will come to market behind GSK’s dolutegravir franchises in Europe as in the US • Source: Shutterstock

More from New Products

More from Scrip